At its 2023 Annual General Meeting, Alcon Inc. (SIX/NYSE: ALC) – the world’s top eye care provider – made a groundbreaking announcement: all proposed resolutions were unanimously approved. Alcon’s commitment to helping people see brilliantly propelled them to this momentous achievement.
Today’s Annual General Meeting was attended by a total of 321,168,907 shares, each with a nominal value of CHF 0.04, collectively amounting to an impressive CHF 12,846,756.28.
Shareholders have once again voted to re-elect F. Michael Ball as Chair of the Board of Directors and all the other members of the Board, Lynn Bleil, Raquel Bono, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel and Dieter Spälti, for a one-year term. This marks another year of trust and dedication that the shareholders have demonstrated towards the Board of Directors, and they are sure to continue to serve with distinction.
Shareholders have re-elected Thomas Glanzmann, Karen May, Scott Maw and Ines Pöschel to serve on the Compensation Committee for the upcoming year. With their leadership, the Committee will continue to work towards ensuring that employees are rewarded fairly and equitably for their contributions to the company.
The Board of Directors and the Executive Committee members have been granted discharge of their duties for the 2022 financial year. This signifies a milestone that brings an end to a year of hard work, dedication, and commitment to the organization.
Shareholders overwhelmingly gave their seal of approval to both the maximum aggregate amount of compensation for the Board of Directors and the Executive Committee for the 2024 term, as well as the 2022 Compensation Report, in two separate binding votes. This affirmation of the Board and Executive Committee’s performance is a satisfying sign of investor confidence in the organization.
Shareholders approved a proposal by the Board of Directors to amend the Articles of Incorporation of Alcon Inc. to meet the requirements of the new Swiss corporate law that took effect on January 1, 2023, as well as to uphold current best corporate governance practices.
“It was a delight to host our first in-person AGM in Lausanne, and I am deeply grateful for the enthusiasm and commitment of our shareholders. With their trust and backing, we will pursue our mission of helping the world See Brilliantly.”
Alcon shareholders gave their vote of confidence in Alcon Inc., approving the annual operating and financial review, as well as the company’s financial statements for 2022. By doing so, they provided affirmation that Alcon Inc. is on track to continue its successful growth and development.
Shareholders gave their approval for a generous dividend of CHF 0.21 per share, after the appropriation of the proposed dividend, the remaining available earnings will be carried forward. This dividend is an indication of the company’s strong financial performance and generous shareholder returns.
At the 2023 AGM, Pricewaterhouse Coopers SA, Geneva was re-elected as statutory auditors for the upcoming financial year. In addition, Hartmann Dreyer Attorneys-at-Law was also re-elected as the independent representative, ensuring continued oversight and accountability until the 2024 AGM. This decision ensures that the company’s financials will remain well audited and monitored.
About Alcon
For over 75 years, Alcon has been the global leader in eye care, helping people see the world brilliantly. Our expansive portfolio of Surgical and Vision Care products touches the lives of people in over 140 countries each year, relieving the burden of conditions like cataracts, glaucoma, retinal diseases, and refractive errors.
Our dedicated team of more than 25,000 associates are passionate about innovating and enhancing the quality of life through our products, partnerships with Eye Care Professionals, and programs that promote access to quality eye care. We are committed to helping people see their best and live their best lives.